WaveMan
WaveMan · Company
ABOS · Acumen Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ABOS Acumen Pharmaceuticals (ABOS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001576885
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
52
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $20.9K priced

What the filings say about ABOS

Insiders, 180 days
-$89.7K net sold
2 sellers · 0% of sales under a 10b5-1 plan

Acumen Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Acumen Pharmaceuticals, Inc. insiders sold a net $89.7K of stock across 75 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Porter Derrell
Director
SELL
2026-06-17 SEC
13,040
$30.4K
+0.4%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jun 16, 2026.
  • The trade is 36.7% of the 35,500 shares held after it.
  • 1 other insider sold within 30 days.
  • 52 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Porter Derrell sold about $30.4K of ABOS on Jun 17, 2026; 1 other insider sold within 30 days and 52 funds added in the latest 13F quarter.
Porter Derrell
Director
SELL
2026-06-17 SECtraded 2026-06-16
12,800
$29.8K
+0.4%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Jun 15, 2026.
  • The trade is 36.1% of the 35,500 shares held after it.
  • 1 other insider sold within 30 days.
  • 52 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Porter Derrell sold about $29.8K of ABOS on Jun 16, 2026; 1 other insider sold within 30 days and 52 funds added in the latest 13F quarter.
Porter Derrell
Director
SELL
2026-06-17 SECtraded 2026-06-15
6,460
$15.2K
+0.4%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 13.4% of the 48,300 shares held after it.
  • 1 other insider sold within 30 days.
  • 52 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Porter Derrell sold about $15.2K of ABOS on Jun 15, 2026; 1 other insider sold within 30 days and 52 funds added in the latest 13F quarter.
Fountain Nathan B
Director
SELL
2026-06-10 SECtraded 2026-06-09
6,400
$14.3K
-4.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 6, 2021.
  • The trade is 13.3% of the 48,150 shares held after it.
  • 1 other insider sold within 30 days.
  • 52 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Fountain Nathan B sold about $14.3K of ABOS on Jun 9, 2026; 1 other insider sold within 30 days and 52 funds added in the latest 13F quarter.
Meisner Derek M
Chief Legal Officer & Corp Sec
SELL
2026-03-10 SECtraded 2026-03-06
2,090
$6.8K
-32.6%
Context
  • 18 earlier Form 4 trades (code P or S) here by this insider (18 sales), the last on Feb 27, 2026.
  • The trade is 1.2% of the 173,999 shares held after it.
  • No other insider sold within 30 days.
  • 52 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Legal Officer & Corp Sec Meisner Derek M sold about $6.8K of ABOS on Mar 6, 2026; 52 funds added in the latest 13F quarter.
75 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 70 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$89.7K over 180 days
more than 56% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
52 funds bought in last quarter
below 52% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
8.3% of the float short (float per yahoo 2026-10-26) · 4.8 days to cover · settled 2026-09-30
below 53% of Pharma & Biotech
What changed in the last 30 days
Oct 27Insider selling stopped: no sales in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch ABOS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+22.7%12M
-16%+17%+49%+82%2025-102025-122026-022026-042026-062026-082026-10 2026-01-07 · OConnell Daniel Joseph sold $75.1K2026-01-08 · Meisner Derek M sold $54.8K2026-01-26 · Meisner Derek M sold $45.3K2026-06-17 · Porter Derrell sold $30.4K2026-06-16 · Porter Derrell sold $29.8K2026-02-27 · Meisner Derek M sold $28.3K2026-01-09 · OConnell Daniel Joseph sold $22.8K2026-01-07 · Meisner Derek M sold $20.0K2026-01-21 · OConnell Daniel Joseph sold $16.9K2026-06-15 · Porter Derrell sold $15.2K2026-01-08 · OConnell Daniel Joseph sold $14.8K2026-01-12 · Meisner Derek M sold $14.6K2026-06-09 · Fountain Nathan B sold $14.3K2026-01-06 · Meisner Derek M sold $14.0K2026-01-06 · Siemers Eric sold $13.5K2026-01-08 · Zuga Matt sold $12.5K2026-01-08 · Meisner Derek M sold $12.4K2026-01-08 · Doherty James J. sold $11.8K2026-01-23 · Meisner Derek M sold $10.7K2026-01-06 · OConnell Daniel Joseph sold $10.1K2026-01-06 · Zuga Matt sold $10.0K2026-01-12 · OConnell Daniel Joseph sold $9.3K2026-01-05 · OConnell Daniel Joseph sold $9.2K2026-01-09 · Meisner Derek M sold $9.2K2026-01-07 · Zuga Matt sold $8.2K2026-01-28 · Meisner Derek M sold $8.0K2026-01-05 · Zuga Matt sold $7.8K2026-01-05 · Siemers Eric sold $7.8K2026-01-05 · Meisner Derek M sold $7.8K2026-01-05 · Barton Russell sold $7.8K2026-01-06 · Meisner Derek M sold $7.5K2026-01-06 · Barton Russell sold $7.1K2026-03-06 · Meisner Derek M sold $6.8K2026-01-08 · Barton Russell sold $6.6K2026-01-22 · OConnell Daniel Joseph sold $5.1K2026-01-21 · Zuga Matt sold $4.5K2026-01-21 · Siemers Eric sold $4.2K2026-01-21 · Barton Russell sold $4.2K2026-01-21 · Meisner Derek M sold $4.1K2026-01-07 · Doherty James J. sold $3.4K2026-01-07 · Zuga Matt sold $3.4K2026-01-07 · Meisner Derek M sold $3.4K
Insider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ABOS: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
20,992,669 sh
$56.1M
Sands Capital Alternatives, LLC
3,720,105 sh
$9.9M
BlackRock, Inc.
2,490,115 sh
$6.6M
Alyeska Investment Group, L.P.
2,454,754 sh
$6.6M
FRANKLIN RESOURCES INC
2,305,096 sh
$6.2M

Congress trades in ABOS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ABOS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ABOS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Ultra-Small Company Fund
$200.2K position · as of 2026-06-30
0.2%
Ultra-Small Company Market Fund
$234.6K position · as of 2026-06-30
0.2%
Franklin Biotechnology Discovery Fund
$1.8M position · as of 2026-07-31
0.2%
iShares Micro-Cap ETF
$423.5K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$28.6K position · as of 2026-06-30
0.0%
Fidelity Small Cap Value Index Fund
$175.8K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
3 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
2
Phase 1
0 active
1
Phase 2
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $89.7K sold by insiders over 180 days, 52 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ABOS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$91.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.55x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Cash flow to debt
-2.91x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Return on equity
-120.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-73.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-97.5%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$136.3M
market value at close 2026-10-26 on 2026-08-07 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
FCF yield
-55.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$123.8M-$114.0M-$61.1M-$45.2M
Net income-$121.3M-$102.3M-$52.4M-$42.9M
EPS (diluted)-2.00-1.71-1.08-1.06
Operating cash flow-$115.5M-$86.2M-$43.1M-$35.2M
Cash$54.0M$35.6M$66.9M$130.1M
Long-term debt$22.4M$29.4M$29.9M$0
SEC XBRL, fiscal years, as known on 2026-10-27

ABOS Stock Sonar score 5/7 axes

Find similar shapesCompare

ABOS ranks highest on institutional and government (48th percentile) and risk and compliance (45th), and lowest on insider conviction (27th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
29
Inputs
  • Return on equity-120.5% · 28 pct, sector of 545
  • Return on assets-73.0% · 32 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-97.5% · 26 pct, sector of 576
Financial health
33
Inputs
  • Debt to equity0.55x · 29 pct, sector of 352
  • Cash flow to debt-2.91x · 37 pct, sector of 371
Insider conviction
27
Inputs
  • Net Form 4 buying (codes P and S), 180d-$90K · 54 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
48
Inputs
  • Funds adding, latest quarter52 · 48 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
45
Inputs
  • Short interest, % of float+8.3% · 45 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ABOS filings, in plain words

Are Acumen Pharmaceuticals insiders buying or selling ABOS?

In the 180 days to 2026-10-27, Acumen Pharmaceuticals insiders were net sellers, a net $89.7K across purchases and sales reported on Form 4, by 2 sellers.

Read the full summary

In the 180 days to 2026-10-27, Acumen Pharmaceuticals insiders were net sellers of ABOS, a net $89.7K across purchases and sales reported on Form 4 by 2 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies